Science 37 SPAC

Clinical Trial Model is Ripe for Disruption. Traditional Site-Centric Model is Not Working... Clinical Trial model has Sponsor not changed in >90 years ■ ■ Multiple legacy technologies with technical debt 1920s Poorly integrated systems lead to redundant resources and duplicate work Redundant processes to fully leverage new technologies and workflow Traditional Clinical Trials 2010s Science 37 Site Coordinator Investigator Nurse Contract Research Associates Patients DIDI of Declining Performance 1 80%* TRIALS EXPERIENCE DELAYS N 2 20%* AVG. PATIENT DROPOUT RATE 3 14%* MINORITIES REPRESENTED 4 7-13 YEARS TO LAUNCH A DRUG 1. Source: Article from Drug Development & Drug delivery https://drug-dev.com/cost-of-disrupted-clinical-research-due-to-covid-19-equates-to-10-billion-potential-study-delays 2. Source: Tufts Center for the Study of Drug Development - Impact Report - Volume 22 Number 1-January/February 2020: https://static1.squarespace.com/static/5a9eb0c8e2ccd1158288d8dc/t/5e303c3dd4520c015cb8a4b1/1580219453985/Jan Feb2020_CropSummary.JPG 3. Source: Article from Nature - When will clinical trials finally reflect diversity? - 09 May 2018: https://www.nature.com/articles/d41586-018-05049-5 4. Source: Tufts Center for the Study of Drug Development - Impact Report - Volume 20 Number 3-May/June 2018 as it relates to non-orphan drugs: https://static1.squarespace.com/static/5a9eb0c8e2ccd1158288d8dc/t/5af455f9352f53cd2156399e/1525962233431/summary_mayjune 18.pdf%20 13

View entire presentation